Related Experiment Video

Updated: Jul 15, 2026

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

Plasma lipid peroxidation and progression of disability in multiple sclerosis

M Koch1, J Mostert, A V Arutjunyan

  • 1Department of Neurology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands. m.w.koch@neuro.umcg.nl

European Journal of Neurology
|April 18, 2007
PubMed

Insights

Oxidative stress markers in the blood are elevated in multiple sclerosis (MS) patients. However, these markers do not correlate with disease progression or disability in MS patients over five years.

Area of Science:

  • Neuroscience
  • Biochemistry
  • Immunology

Background:

  • Oxidative stress is a proposed factor in multiple sclerosis (MS) pathophysiology.
  • The link between oxidative stress and MS disease progression remains unclear.

Purpose of the Study:

  • To investigate the association between plasma lipid peroxidation and disability progression in multiple sclerosis patients.
  • To determine if oxidative stress levels predict disease worsening in MS.

Main Methods:

  • Plasma fluorescent lipid peroxidation products (PFLPP) were measured in 23 RRMS, 32 SPMS, 24 PPMS patients, and 30 controls.
  • Disability progression was assessed over 5 years using EDSS and MSSS.
  • Patients with recent relapses were excluded.

Main Results:

  • Plasma PFLPP levels were significantly higher in MS patients compared to healthy controls (P < 0.0001).
  • No significant difference in PFLPP levels was observed between patients with benign and progressive MS.
  • No correlation was found between PFLPP levels and EDSS score changes or MSSS progression rates.

Conclusions:

  • Elevated plasma oxidative stress markers are present in MS patients.
  • Plasma lipid peroxidation levels do not appear to be related to the progression of disability in multiple sclerosis over a 5-year period.

More Related Videos

A Stably Established Two-Point Injection of Lysophosphatidylcholine-Induced Focal Demyelination Model in Mice04:55

A Stably Established Two-Point Injection of Lysophosphatidylcholine-Induced Focal Demyelination Model in Mice

Published on: May 11, 2022

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Secondary Spinal Cord Injury llI: Pathophysiology01:25

Secondary Spinal Cord Injury llI: Pathophysiology

Early Ischemia and Ionic ImbalanceWithin minutes of spinal cord injury, a secondary cascade begins, progressing over hours to weeks. Vascular damage reduces blood flow, causing ischemia and mitochondrial dysfunction. ATP depletion leads to ion pump failure, membrane depolarization, sodium influx, potassium efflux, and water accumulation, resulting in cellular swelling. Increased intracellular calcium further disrupts mitochondria and accelerates cellular injury.Excitotoxicity and Neuronal...
Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...